Home/Pipeline/Elrexfio

Elrexfio

Multiple Myeloma

ApprovedActive (Line Extensions)

Key Facts

Indication

Multiple Myeloma

Phase

Approved

Status

Active (Line Extensions)

Company

Pfizer

About Pfizer

Pfizer's mission is to deliver 'Breakthroughs that change patients' lives' through scientific innovation across a diversified portfolio of therapeutics and vaccines. Its strategic achievements include the rapid development and global commercialization of the COVID-19 vaccine Comirnaty, establishing a leading mRNA platform, and a disciplined pipeline expansion into high-growth areas like obesity and oncology. The company's strategy focuses on sharpening its R&D focus on transformative science, optimizing its cost structure, and deploying capital for strategic business development to drive long-term growth post-pandemic.

View full company profile

Therapeutic Areas

Internal Medicine Oncology Vaccines Inflammation & Immunology Rare Disease

Other Multiple Myeloma Drugs

Drug	Company	Phase	Status
PRG1801 (Anti-BCMA CAR-T)	Pregene Biopharma	Phase 1	Active
CAR-NK Therapy	Pregene Biopharma	Phase 1	Active (recruiting)
Tasquinimod	Active Biotech	Preclinical	Active (Academic Partnership)
BCMA CAR-T	Simnova Biotherapeutics	Phase 1	Active
BCMA panCAR (via Orna partnership)	Simnova Biotherapeutics	Preclinical	Active
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
Kyprolis® (carfilzomib)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
inobrodib (CCS1477)	CellCentric	Phase 1/2	Active
ISB 2001	Ichnos Glenmark Innovation	Phase 1b	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Hemady	Dexcel Pharma USA	Approved	Commercial
AV-353	AVEO Oncology	Pre-clinical	Active